Testing HSK42360 for solid tumors with BRAF V600 mutation
Part of Cancer clinical trials.
This trial tests a new drug, HSK42360, for people with advanced solid tumors that have a specific gene change called BRAF V600. It may be an option if other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your cancer has a BRAF V600 mutation confirmed by a lab test.
- Your tumor is advanced or has spread, and standard treatments no longer work or are not an option.
- You are willing to provide a blood or tumor sample if possible.
- Your brain metastases (if any) are stable, and you are not currently having seizures or on high doses of steroids.
- Your heart, liver, kidney, and blood cell counts are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests a new drug, HSK42360, for children with recurrent brain tumors that have a specific gene change called BRAF V600. The goal is to see if the drug can help when standard treatments have stopped working.
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.